New CAR-T therapy aims to beat High-Risk lymphoma in early treatment
NCT ID NCT04661020
First seen Apr 10, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This study tests a treatment called CD19 CAR-T therapy for people newly diagnosed with a fast-growing type of large B-cell lymphoma that is hard to treat. About 40 adults will receive the therapy to see if it can make the cancer disappear completely. The goal is to improve outcomes for patients with high-risk disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital，College of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.